The HOPE-3 Trial
Blood Pressure Lowering in People at Moderate Risk

Purpose: For primary prevention in moderate/intermediate-risk patients, to evaluate whether the use of candesartan 16 mg/HCT 12.5 mg to lower blood pressure reduces the risk for strokes and heart attacks.

Trial Design: Phase 4 randomized, double-blinded, international trial. Candesartan 16 mg/HCT 12.5 mg daily vs. placebo. 12,705 women 60 years or older and men 55 years or older. No history of stroke or heart disease, but at least 1 CV risk factor. F/U 5.6 years. Mean baseline BP = 138.1/81.9 mm Hg.

Primary Endpoint: Composite of cardiovascular events (heart attacks, strokes, deaths)

Secondary Endpoint: Cardiac arrest (resuscitated), HF, revascularization

Trial Results	Candesartan 16 mg/HCT 12.5 mg	Placebo	P
Mean BP Decrease from baseline	10.0±13.1 mm Hg	4.0±12.9 mm Hg	
Primary endpoints	4.1%	4.4%	0.40
Secondary endpoints	4.9%	5.2%	0.51
Highest BP patients (SBP >143.5 mmHg)	P= 0.02 for primary and 0.009 for secondary endpoints		

Conclusions: This drug combination did not result in a reduction of the rates of the primary endpoints. Those with the highest BP's in this group were noted to have significantly reduced 1° endpoint events.

American Heart Association | American Stroke Association
life is why™

Presented by: Eva M. Lonn, ACC.16,Chicago, IL.